摘要
The results of treatment for childhood acute lymphoblastic leukemia (ALL) have improved dramatically over the past three decades. The authors present the long-term outcome of patients (n = 151) with ALL enrolled in 4 consecutive clinical trials conducted from 1982 to 1993 at Mackay Memorial Hospital. During this period, the backbone of the treatment remained relatively unchanged, including a 3- to 4-drug remission induction, central nervous system (CNS)-directed therapy, and cyclic pulses of vincristine and dexamethasone during maintenance therapy. More intensive therapy, consisting of reintensification and addition of more drugs during maintenance, was reserved for high-risk and very-high-risk paitents. The overall survival and event-free survival (± 1 SE) were 70 ± 4.1% and 64 ± 4.3%, respectively, with follow-up ranging from 7.6 to 18.7 years (median 12.2 year). The isolated CNS relapse rate was 4.3%. The dropout rate significantaly decreased from 35% in 1982-1984 to 0% in 1991-1993. Although the patient population is small, the overall results for childhood ALL at the authors' hospital are encouraging as compared to earlier reports in Taiwan.
| 原文 | 英語 |
|---|---|
| 頁（從 - 到） | 19-29 |
| 頁數 | 11 |
| 期刊 | Pediatric Hematology and Oncology |
| 卷 | 19 |
| 發行號 | 1 |
| DOIs | |
| 出版狀態 | 已發佈 - 2002 |
| 對外發佈 | Yes |
指紋
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology
- Cancer Research
- Management of Technology and Innovation
引用此文
Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan. / Liu, Hsi Che; Chen, Shu Huey; Chang, Kou Hwa; Chiang, Le Chiao; Liu, Chin Yueh; Chang, Huei Lan; Tsai, Li Li; Liang, Der Cherng.
於: Pediatric Hematology and Oncology, 卷 19, 編號 1, 2002, p. 19-29.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan
AU - Liu, Hsi Che
AU - Chen, Shu Huey
AU - Chang, Kou Hwa
AU - Chiang, Le Chiao
AU - Liu, Chin Yueh
AU - Chang, Huei Lan
AU - Tsai, Li Li
AU - Liang, Der Cherng
PY - 2002
Y1 - 2002
N2 - The results of treatment for childhood acute lymphoblastic leukemia (ALL) have improved dramatically over the past three decades. The authors present the long-term outcome of patients (n = 151) with ALL enrolled in 4 consecutive clinical trials conducted from 1982 to 1993 at Mackay Memorial Hospital. During this period, the backbone of the treatment remained relatively unchanged, including a 3- to 4-drug remission induction, central nervous system (CNS)-directed therapy, and cyclic pulses of vincristine and dexamethasone during maintenance therapy. More intensive therapy, consisting of reintensification and addition of more drugs during maintenance, was reserved for high-risk and very-high-risk paitents. The overall survival and event-free survival (± 1 SE) were 70 ± 4.1% and 64 ± 4.3%, respectively, with follow-up ranging from 7.6 to 18.7 years (median 12.2 year). The isolated CNS relapse rate was 4.3%. The dropout rate significantaly decreased from 35% in 1982-1984 to 0% in 1991-1993. Although the patient population is small, the overall results for childhood ALL at the authors' hospital are encouraging as compared to earlier reports in Taiwan.
AB - The results of treatment for childhood acute lymphoblastic leukemia (ALL) have improved dramatically over the past three decades. The authors present the long-term outcome of patients (n = 151) with ALL enrolled in 4 consecutive clinical trials conducted from 1982 to 1993 at Mackay Memorial Hospital. During this period, the backbone of the treatment remained relatively unchanged, including a 3- to 4-drug remission induction, central nervous system (CNS)-directed therapy, and cyclic pulses of vincristine and dexamethasone during maintenance therapy. More intensive therapy, consisting of reintensification and addition of more drugs during maintenance, was reserved for high-risk and very-high-risk paitents. The overall survival and event-free survival (± 1 SE) were 70 ± 4.1% and 64 ± 4.3%, respectively, with follow-up ranging from 7.6 to 18.7 years (median 12.2 year). The isolated CNS relapse rate was 4.3%. The dropout rate significantaly decreased from 35% in 1982-1984 to 0% in 1991-1993. Although the patient population is small, the overall results for childhood ALL at the authors' hospital are encouraging as compared to earlier reports in Taiwan.
KW - Acute lymphoblastic leukemia
KW - Epirubicin
KW - Long-term treatment results
UR - http://www.scopus.com/inward/record.url?scp=0036088860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036088860&partnerID=8YFLogxK
U2 - 10.1080/088800102753356158
DO - 10.1080/088800102753356158
M3 - Article
C2 - 11787864
AN - SCOPUS:0036088860
VL - 19
SP - 19
EP - 29
JO - Pediatric Hematology and Oncology
JF - Pediatric Hematology and Oncology
SN - 0888-0018
IS - 1
ER -